Affordable Access

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)

Authors
  • Liang, Xu
  • Briaux, Adrien
  • Becette, Véronique
  • Benoist, Camille
  • Boulai, Anais
  • Chemlali, Walid
  • Schnitzler, Anne
  • Baulande, Sylvain
  • Rivera, Sofia
  • Mouret-Reynier, Marie-Ange
  • Bouvet, Laurence Venat
  • De La Motte Rouge, Thibaut
  • Lemonnier, Jérôme
  • Lerebours, Florence
  • Callens, Céline
Publication Date
Dec 01, 2018
Source
HAL-INRIA
Keywords
Language
English
License
Unknown
External links

Abstract

Postmenopausal women with large, hormone receptor (HR)-positive/HER2-negative and low-proliferative breast cancer derived a benefit from neoadjuvant endocrine therapy (NET) in the CARMINA02 trial. This study was designed to correlate gene expression and mutation profiles with both response to NET and prognosis.

Report this publication

Statistics

Seen <100 times